ES2594706T3 - Péptidos biológicamente activos - Google Patents
Péptidos biológicamente activos Download PDFInfo
- Publication number
- ES2594706T3 ES2594706T3 ES09743243.9T ES09743243T ES2594706T3 ES 2594706 T3 ES2594706 T3 ES 2594706T3 ES 09743243 T ES09743243 T ES 09743243T ES 2594706 T3 ES2594706 T3 ES 2594706T3
- Authority
- ES
- Spain
- Prior art keywords
- seq
- bls
- peptide
- ttds
- wdlyfeivw
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US932608P | 2008-04-17 | 2008-04-17 | |
| US9326P | 2008-04-17 | ||
| US11305508P | 2008-11-10 | 2008-11-10 | |
| US113055P | 2008-11-10 | ||
| PCT/US2009/040857 WO2009137256A1 (fr) | 2008-04-17 | 2009-04-16 | Peptides biologiquement actifs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2594706T3 true ES2594706T3 (es) | 2016-12-22 |
Family
ID=40887122
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES16172509T Active ES2739676T3 (es) | 2008-04-17 | 2009-04-16 | Péptidos biológicamente activos |
| ES09743243.9T Active ES2594706T3 (es) | 2008-04-17 | 2009-04-16 | Péptidos biológicamente activos |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES16172509T Active ES2739676T3 (es) | 2008-04-17 | 2009-04-16 | Péptidos biológicamente activos |
Country Status (19)
| Country | Link |
|---|---|
| US (6) | US8563688B2 (fr) |
| EP (2) | EP3115370B1 (fr) |
| JP (3) | JP6038452B2 (fr) |
| KR (2) | KR101434712B1 (fr) |
| CN (2) | CN102007140B (fr) |
| AR (1) | AR071478A1 (fr) |
| AU (1) | AU2009244635B2 (fr) |
| BR (1) | BRPI0911203A2 (fr) |
| CA (1) | CA2721694C (fr) |
| DK (2) | DK2279200T3 (fr) |
| ES (2) | ES2739676T3 (fr) |
| HK (2) | HK1154255A1 (fr) |
| MX (1) | MX2010011397A (fr) |
| NZ (1) | NZ588200A (fr) |
| PL (1) | PL2279200T3 (fr) |
| PT (1) | PT2279200T (fr) |
| SG (2) | SG10201809286XA (fr) |
| TW (2) | TWI541020B (fr) |
| WO (1) | WO2009137256A1 (fr) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI541020B (zh) * | 2008-04-17 | 2016-07-11 | 巴克斯歐塔公司 | 生物活性胜肽 |
| AU2010290077C1 (en) | 2009-08-24 | 2015-12-03 | Bioverativ Therapeutics Inc. | Coagulation factor IX compositions and methods of making and using same |
| CN103262532B (zh) | 2010-07-19 | 2018-03-09 | 杜比实验室特许公司 | 用于经采样复用的图像和视频数据的增强方法 |
| PL2717898T3 (pl) | 2011-06-10 | 2019-06-28 | Bioverativ Therapeutics Inc. | Związki o działaniu prokoagulacyjnym i sposoby ich stosowania |
| EP3549953A1 (fr) | 2012-02-15 | 2019-10-09 | Bioverativ Therapeutics Inc. | Protéines de facteur viii de recombinaison |
| ES2771208T3 (es) | 2012-02-15 | 2020-07-06 | Bioverativ Therapeutics Inc | Composiciones de factor VIII y métodos de preparación y uso de las mismas |
| JP6246894B2 (ja) * | 2013-06-11 | 2017-12-13 | シージェイ チェイルジェダング コーポレイション | Ｌ−イソロイシンを生産する微生物及びこれを用いたｌ−イソロイシン製造方法 |
| WO2015023891A2 (fr) | 2013-08-14 | 2015-02-19 | Biogen Idec Ma Inc. | Fusions de facteur vii-xten et leurs utilisations |
| WO2015023894A1 (fr) | 2013-08-14 | 2015-02-19 | Biogen Idec Ma Inc. | Protéines de facteur viii de recombinaison |
| EP3065769A4 (fr) | 2013-11-08 | 2017-05-31 | Biogen MA Inc. | Composé de fusion procoagulant |
| US20160039876A1 (en) | 2014-03-28 | 2016-02-11 | Claresa Levetan | Insulin independence among patients with diabetes utilizing an optimized hamster reg3 gamma peptide |
| JP6484468B2 (ja) * | 2014-06-03 | 2019-03-13 | ＡｖａｎＳｔｒａｔｅ株式会社 | ガラス板製造方法およびガラス板製造装置 |
| GB201410507D0 (en) * | 2014-06-12 | 2014-07-30 | Univ Bath | Drug delivery enhancement agents |
| EA201890423A1 (ru) | 2015-08-03 | 2018-07-31 | Биовератив Терапьютикс Инк. | Слитые белки фактора ix, способы их получения и применения |
| US11111271B2 (en) | 2016-09-28 | 2021-09-07 | Cohbar, Inc. | Therapeutic peptides |
| AU2018215092A1 (en) | 2017-01-31 | 2019-08-29 | Bioverativ Therapeutics Inc. | Factor IX fusion proteins and methods of making and using same |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4447356A (en) * | 1981-04-17 | 1984-05-08 | Olivera Baldomero M | Conotoxins |
| IT1190891B (it) | 1982-06-24 | 1988-02-24 | Anic Spa | Metodo per la sintesi in fase solida di polipeptidi retroinvertiti |
| US5122614A (en) | 1989-04-19 | 1992-06-16 | Enzon, Inc. | Active carbonates of polyalkylene oxides for modification of polypeptides |
| US5093317A (en) * | 1989-06-05 | 1992-03-03 | Cephalon, Inc. | Treating disorders by application of insulin-like growth factor |
| JPH0725794B2 (ja) * | 1990-03-23 | 1995-03-22 | 呉羽化学工業株式会社 | 新規なペプチド |
| US5595732A (en) | 1991-03-25 | 1997-01-21 | Hoffmann-La Roche Inc. | Polyethylene-protein conjugates |
| US6037452A (en) * | 1992-04-10 | 2000-03-14 | Alpha Therapeutic Corporation | Poly(alkylene oxide)-Factor VIII or Factor IX conjugate |
| US5439686A (en) * | 1993-02-22 | 1995-08-08 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor |
| BR9405798A (pt) | 1993-02-22 | 1995-12-12 | Vivorx Pharmaceuticals Inc | Métodos para liberação in vivo de material biológico e composições úteis dos mesmos |
| WO1996021024A1 (fr) * | 1994-12-30 | 1996-07-11 | Asgrow Seed Company | Gene de replicase du virus de la decoloration foliaire de la papaye |
| US5532153A (en) * | 1995-03-23 | 1996-07-02 | New England Biolabs, Inc. | Method for cloning and producing the SacI restriction endonuclease |
| US7279548B2 (en) * | 1996-04-03 | 2007-10-09 | Cytogen Corporation | Identification and isolation of novel polypeptides having WW domains and methods of using same |
| US6197526B1 (en) * | 1999-01-04 | 2001-03-06 | Dyax Corp. | Polypeptides for binding human factor VIII and fragments of human factor VIII |
| US7109170B2 (en) | 1999-06-16 | 2006-09-19 | Saint Louis University | Region of factor IXa protease domain that interacts with factor VIIIa and methods therefor |
| US6624289B1 (en) * | 1999-06-16 | 2003-09-23 | Saint Louis University | Region of factor IXa protease domain that interacts with factor VIIIa and methods therefor |
| JP2003503426A (ja) | 1999-07-02 | 2003-01-28 | ジェネンテック・インコーポレーテッド | ＦＶＩＩａアンタゴニスト |
| AT411997B (de) | 1999-09-14 | 2004-08-26 | Baxter Ag | Faktor ix/faktor ixa aktivierende antikörper und antikörper-derivate |
| WO2001039799A2 (fr) * | 1999-12-06 | 2001-06-07 | Panacea Pharmaceuticals, Llc. | Desensibilisation passive |
| US20020197266A1 (en) * | 2000-02-08 | 2002-12-26 | Waldemar Debinski | Immunotherapy using interleukin 13 receptor subunit alpha 2 |
| EP1385872A4 (fr) * | 2001-05-11 | 2004-12-15 | Res Dev Foundation | Inhibiteurs de recepteur activateur de nf-kappa b et utilisations de ces inhibiteurs |
| FR2830865B1 (fr) * | 2001-10-17 | 2004-10-22 | Centre Nat Rech Scient | Leurres peptidiques pour la preparation de medicaments destines a la prevention ou au traitement des pathologies auto-immunes, ou des troubles lies a l'apparition d'anticorps diriges contre des proteines exogenes |
| US20060204503A1 (en) * | 2005-01-31 | 2006-09-14 | Biogen Idec Ma Inc. | Treatment of cancer using antibodies to polypeptides differentially expressed in human lung tumors |
| WO2007065691A2 (fr) * | 2005-12-07 | 2007-06-14 | Technische Universität München | Petits ligands d'affinite peptidiques et peptido-mimetiques pour le facteur viii et pour des proteines similaires au facteur viii |
| KR20080087148A (ko) | 2006-01-04 | 2008-09-30 | 두-쿱 테크놀로지스 리미티드 | 저온보호 조성물 및 그 이용방법 |
| TWI541020B (zh) * | 2008-04-17 | 2016-07-11 | 巴克斯歐塔公司 | 生物活性胜肽 |
-
2009
- 2009-04-15 TW TW098112448A patent/TWI541020B/zh active
- 2009-04-15 TW TW103127214A patent/TWI573806B/zh active
- 2009-04-15 AR ARP090101328A patent/AR071478A1/es active IP Right Grant
- 2009-04-16 SG SG10201809286XA patent/SG10201809286XA/en unknown
- 2009-04-16 CN CN200980114502.4A patent/CN102007140B/zh active Active
- 2009-04-16 PL PL09743243T patent/PL2279200T3/pl unknown
- 2009-04-16 JP JP2011505212A patent/JP6038452B2/ja active Active
- 2009-04-16 KR KR1020107025687A patent/KR101434712B1/ko active IP Right Grant
- 2009-04-16 EP EP16172509.8A patent/EP3115370B1/fr active Active
- 2009-04-16 MX MX2010011397A patent/MX2010011397A/es active IP Right Grant
- 2009-04-16 CA CA2721694A patent/CA2721694C/fr active Active
- 2009-04-16 ES ES16172509T patent/ES2739676T3/es active Active
- 2009-04-16 KR KR1020137024826A patent/KR101606248B1/ko active IP Right Grant
- 2009-04-16 NZ NZ588200A patent/NZ588200A/xx unknown
- 2009-04-16 WO PCT/US2009/040857 patent/WO2009137256A1/fr active Application Filing
- 2009-04-16 ES ES09743243.9T patent/ES2594706T3/es active Active
- 2009-04-16 CN CN201610040575.5A patent/CN105524163A/zh active Pending
- 2009-04-16 SG SG10201608071YA patent/SG10201608071YA/en unknown
- 2009-04-16 BR BRPI0911203A patent/BRPI0911203A2/pt not_active Application Discontinuation
- 2009-04-16 AU AU2009244635A patent/AU2009244635B2/en active Active
- 2009-04-16 DK DK09743243.9T patent/DK2279200T3/en active
- 2009-04-16 DK DK16172509.8T patent/DK3115370T3/da active
- 2009-04-16 PT PT97432439T patent/PT2279200T/pt unknown
- 2009-04-16 EP EP09743243.9A patent/EP2279200B1/fr active Active
- 2009-04-16 US US12/425,277 patent/US8563688B2/en active Active
-
2011
- 2011-08-03 HK HK11108062.3A patent/HK1154255A1/zh unknown
- 2011-09-21 US US13/238,751 patent/US8822638B2/en active Active
-
2013
- 2013-12-20 JP JP2013263345A patent/JP5977223B2/ja active Active
-
2014
- 2014-07-24 US US14/340,231 patent/US9206234B2/en active Active
-
2015
- 2015-11-13 US US14/941,163 patent/US9598464B2/en active Active
-
2016
- 2016-07-21 JP JP2016143368A patent/JP2017019797A/ja active Pending
- 2016-10-19 HK HK16112064.8A patent/HK1223946A1/zh unknown
-
2017
- 2017-02-27 US US15/443,949 patent/US10287319B2/en active Active
-
2019
- 2019-03-20 US US16/359,763 patent/US10822376B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2594706T3 (es) | Péptidos biológicamente activos | |
| ES2235921T3 (es) | Composiciones para el tratamiento de disfunciones sexuales. | |
| AU2009226910B2 (en) | Protease stabilized, acylated insulin analogues | |
| ES2805094T3 (es) | Inmunoterapia WT1 para enfermedad angiogénica intraocular | |
| ES2633989T3 (es) | Formulación líquida estable de amg 416 (velcalcetida) | |
| US20030022829A1 (en) | Novel antiviral activities primate theta defensins and mammalian cathelicidins | |
| ES2544573T3 (es) | Inhibidores diméricos de afinidad elevada de PSD-95 y su uso para el tratamiento del daño cerebral isquémico y del dolor | |
| KR20220143923A (ko) | Glp-1r 및 gcgr 효능제, 제형 및 사용 방법 | |
| US11299518B2 (en) | Fusion respiratory syncytial virus inhibitors and use thereof | |
| WO2023150375A2 (fr) | Méthodes et compositions de traitement d'infections à la covid | |
| ES2876404T3 (es) | Liofilizado que contiene un péptido cíclico de fórmula X1-GQRETPEGAEAKPWY-X2 para el tratamiento de edemas pulmonares | |
| AU2019202888B2 (en) | Biologically active peptides | |
| AU2012205202B2 (en) | Biologically Active Peptides | |
| AU2013205270B2 (en) | Protease stabilized, acylated insulin analogues | |
| CA2137349C (fr) | Surfactants peptidiques a action pulmonaire et combinaisons therapeutiques |